Xarelto vs Leqvio
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Xarelto | US Leqvio | |
|---|---|---|
| Generic name | rivaroxaban | inclisiran |
| Drug class | Factor Xa Inhibitor | siRNA PCSK9-Lowering Therapy |
| Treats | Blood clots, atrial fibrillation | High cholesterol, cardiovascular disease |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Janssen/Bayer | Novartis |
| Year approved | 2011 | 2021 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $210M | $90M |
| Common side effects | Serious bleeding risk, Bruising, Prolonged bleeding, Spinal/epidural blood clots | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath |
Frequently asked questions
Is Xarelto or Leqvio better?
Neither is universally "better." Xarelto (rivaroxaban) and Leqvio (inclisiran) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xarelto and Leqvio?
Xarelto is a Factor Xa Inhibitor made by Janssen/Bayer, while Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xarelto has the larger estimated TV advertising budget of the two.